Functional antibody fragments complementing each other for a two-component system against unwanted retargeting cell death.
A two-component T cell binding agent system with a cleavable inactive binding partner and cleavage site provides targeted and specific activation of T cells on undesirable cells, addressing the lack of specificity and off-target effects in existing immunotherapies.
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- REVITOPE LTD
- Filing Date
- 2024-07-18
- Publication Date
- 2026-05-25
AI Technical Summary
Existing immunotherapeutic strategies for targeting unwanted cells, such as cancer cells, lack sufficient specificity and can cause undesirable side effects on other cell types, necessitating a more targeted and specific therapeutic approach.
A two-component system comprising a targeted T cell binding agent with a first T cell binding domain that becomes active upon binding to a second T cell binding domain, an inactive binding partner that prevents initial binding, and a cleavage site for separation, allowing localized and specific activation of T cells on undesirable cells.
Enables highly specific activation of T cells on undesirable cells, reducing off-target effects and enhancing therapeutic efficacy.
Smart Images

Figure 0007864778000024 
Figure 0007864778000025 
Figure 0007864778000026